BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 14981992)

  • 1. CCND1 amplification predicts sensitivity to chemotherapy and chemoradiotherapy in head and neck squamous cell carcinoma.
    Ishiguro R; Fujii M; Yamashita T; Tashiro M; Tomita T; Ogawa K; Kameyama K
    Anticancer Res; 2003; 23(6D):5213-20. PubMed ID: 14981992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclin D1 amplification and p16(MTS1/CDK4I) deletion correlate with poor prognosis in head and neck tumors.
    Namazie A; Alavi S; Olopade OI; Pauletti G; Aghamohammadi N; Aghamohammadi M; Gornbein JA; Calcaterra TC; Slamon DJ; Wang MB; Srivatsan ES
    Laryngoscope; 2002 Mar; 112(3):472-81. PubMed ID: 12148857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Image cytometry of cyclin D1: a prognostic marker for head and neck squamous cell carcinomas.
    Liu SC; Zhang SY; Babb JS; Ridge JA; Klein-Szanto AJ
    Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):455-9. PubMed ID: 11352854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amplification of the cyclin D1 gene is associated with tumour subsite, DNA non-diploidy and high S-phase fraction in squamous cell carcinoma of the head and neck.
    Niméus E; Baldetorp B; Bendahl PO; Rennstam K; Wennerberg J; Akervall J; Fernö M
    Oral Oncol; 2004 Jul; 40(6):624-9. PubMed ID: 15063391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up.
    Psyrri A; Kwong M; DiStasio S; Lekakis L; Kassar M; Sasaki C; Wilson LD; Haffty BG; Son YH; Ross DA; Weinberger PM; Chung GG; Zelterman D; Burtness BA; Cooper DL
    J Clin Oncol; 2004 Aug; 22(15):3061-9. PubMed ID: 15284256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glutathione S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors.
    Cullen KJ; Newkirk KA; Schumaker LM; Aldosari N; Rone JD; Haddad BR
    Cancer Res; 2003 Dec; 63(23):8097-102. PubMed ID: 14678959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential marker of oral squamous cell carcinoma aggressiveness detected by fluorescence in situ hybridization in fine-needle aspiration biopsies.
    Miyamoto R; Uzawa N; Nagaoka S; Nakakuki K; Hirata Y; Amagasa T
    Cancer; 2002 Nov; 95(10):2152-9. PubMed ID: 12412169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclin D1 abnormalities and tobacco exposure in head and neck squamous cell carcinoma.
    Davidson BJ; Lydiatt WM; Abate MP; Schantz SP; Chaganti RS
    Head Neck; 1996; 18(6):512-21. PubMed ID: 8902564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The gene ratios c-MYC:cyclin-dependent kinase (CDK)N2A and CCND1:CDKN2A correlate with poor prognosis in squamous cell carcinoma of the head and neck.
    Akervall J; Bockmühl U; Petersen I; Yang K; Carey TE; Kurnit DM
    Clin Cancer Res; 2003 May; 9(5):1750-5. PubMed ID: 12738730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chromosomal translocations involving 11q13 contribute to cyclin D1 overexpression in squamous cell carcinoma of the head and neck.
    Akervall J; Borg A; Dictor M; Jin C; Jin Y; Tanner M; Isola J; Mertens F; Wennerberg J
    Int J Oncol; 2002 Jan; 20(1):45-52. PubMed ID: 11743641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 overexpression.
    Akervall JA; Michalides RJ; Mineta H; Balm A; Borg A; Dictor MR; Jin Y; Loftus B; Mertens F; Wennerberg JP
    Cancer; 1997 Jan; 79(2):380-9. PubMed ID: 9010112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Invasive ductal carcinoma of the breast: study of the number of copies of the CCND1 gene and chromosome 11 using fluorescence in situ hybridization (FISH) in comparison with expression of cyclin D1 protein and estrogen receptors (ER alpha) with immunohistochemical detection].
    Mrhalová M; Kodet R; Strnad P
    Cas Lek Cesk; 2002 Nov; 141(22):708-14. PubMed ID: 12532908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma.
    Brizel DM; Murphy BA; Rosenthal DI; Pandya KJ; Glück S; Brizel HE; Meredith RF; Berger D; Chen MG; Mendenhall W
    J Clin Oncol; 2008 May; 26(15):2489-96. PubMed ID: 18487568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclin A as a predictive factor for chemotherapy response in advanced head and neck cancer.
    Rodriguez-Pinilla M; Rodriguez-Peralto JL; Hitt R; Sanchez JJ; Ballestin C; Diez A; Sanchez-Verde L; Alameda F; Sanchez-Cespedes M
    Clin Cancer Res; 2004 Dec; 10(24):8486-92. PubMed ID: 15623629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EMS1 gene amplification correlates with poor prognosis in squamous cell carcinomas of the head and neck.
    Rodrigo JP; García LA; Ramos S; Lazo PS; Suárez C
    Clin Cancer Res; 2000 Aug; 6(8):3177-82. PubMed ID: 10955801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinctive clinicopathological associations of amplification of the cortactin gene at 11q13 in head and neck squamous cell carcinomas.
    Rodrigo JP; García-Carracedo D; García LA; Menéndez S; Allonca E; González MV; Fresno MF; Suárez C; García-Pedrero JM
    J Pathol; 2009 Mar; 217(4):516-23. PubMed ID: 18991334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensive chemoradiotherapy as a primary treatment for organ preservation in patients with advanced cancer of the head and neck: efficacy, toxic effects, and limitations.
    Hanna E; Alexiou M; Morgan J; Badley J; Maddox AM; Penagaricano J; Fan CY; Breau R; Suen J
    Arch Otolaryngol Head Neck Surg; 2004 Jul; 130(7):861-7. PubMed ID: 15262764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemoradiotherapy laryngeal preservation for advanced hypopharyngeal cancer.
    Tai SK; Yang MH; Wang LW; Tsai TL; Chu PY; Wang YF; Huang JL; Chang SY
    Jpn J Clin Oncol; 2008 Aug; 38(8):521-7. PubMed ID: 18697758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mature results from a randomized Phase II trial of cisplatin plus 5-fluorouracil and radiotherapy with or without tirapazamine in patients with resectable Stage IV head and neck squamous cell carcinomas.
    Le QT; Taira A; Budenz S; Jo Dorie M; Goffinet DR; Fee WE; Goode R; Bloch D; Koong A; Martin Brown J; Pinto HA
    Cancer; 2006 May; 106(9):1940-9. PubMed ID: 16532436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A differential PCR system for the determination of CCND1 (cyclin D1) gene amplification in head and neck squamous cell carcinomas.
    Schneeberger C; Eder S; Swoboda H; Ullrich R; Zeillinger R
    Oral Oncol; 1998 Jul; 34(4):257-60. PubMed ID: 9813719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.